Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sulforadex Licensed for Pharmaceutical Development - Happi
Company News

Sulforadex Licensed for Pharmaceutical Development

Visit Lalilab (Booth No. 662) to learn more about its topical applications.

Evgen Limited, has exercised its option with Lalilab and PharmAgra Labs to enter into a worldwide exclusive license agreement to develop Sulforadex as an oral pharmaceutical for the prevention and treatment of prostate cancer and other cancers.

Concurrently, Lalilab (Booth No. 662) and PharmAgra retain the rights to develop the patented stabilized sulforaphane technology for topical applications; focusing on skin disease, therapeutics and cosmetics. In this regard, they are currently working with several US-based collaborators and are actively seeking other parties interested in commercializing this technology.

The innovation, Sulforadex, is a unique stabilized sulforaphane, extending shelf life and utility from hours to years, making pharmaceutical applications viable for the first time. The composition, based upon a synthetic sulforaphane encapsulated within a sugar structure called an alpha cyclodextrin, represents a material development in realizing the clinical potential as extolled by a substantial body of scientific literature.


More info: Lalilab, Inc., Tel: 919-620-6767; E-mail: info@lalilab.com; Website: www.lalilab.com

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters